<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kirichenko, A.</style></author><author><style face="normal" font="default" size="100%">Lapovok, I.</style></author><author><style face="normal" font="default" size="100%">Baryshev, P.</style></author><author><style face="normal" font="default" size="100%">van de Vijver, D A M C</style></author><author><style face="normal" font="default" size="100%">van Kampen, J. J. A.</style></author><author><style face="normal" font="default" size="100%">Boucher, C A B</style></author><author><style face="normal" font="default" size="100%">Paraskevis, D</style></author><author><style face="normal" font="default" size="100%">Kireev, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs</style></title><secondary-title><style face="normal" font="default" size="100%">VirusesVirusesViruses</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Viruses</style></alt-title><short-title><style face="normal" font="default" size="100%">VirusesViruses</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*A6</style></keyword><keyword><style  face="normal" font="default" size="100%">*founder effect</style></keyword><keyword><style  face="normal" font="default" size="100%">*genetic barrier</style></keyword><keyword><style  face="normal" font="default" size="100%">*Hiv-1</style></keyword><keyword><style  face="normal" font="default" size="100%">*Insti</style></keyword><keyword><style  face="normal" font="default" size="100%">*integrase</style></keyword><keyword><style  face="normal" font="default" size="100%">*L74i</style></keyword><keyword><style  face="normal" font="default" size="100%">*Phylogenetics</style></keyword><keyword><style  face="normal" font="default" size="100%">*polymorphisms</style></keyword><keyword><style  face="normal" font="default" size="100%">*Russia</style></keyword><keyword><style  face="normal" font="default" size="100%">in the collection, analyses, or interpretation of data</style></keyword><keyword><style  face="normal" font="default" size="100%">in the writing</style></keyword><keyword><style  face="normal" font="default" size="100%">of the manuscript, or in the decision to publish the results.</style></keyword><keyword><style  face="normal" font="default" size="100%">of the study</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jul 31</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/08/06</style></edition><volume><style face="normal" font="default" size="100%">12</style></volume><isbn><style face="normal" font="default" size="100%">1999-4915</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The increasing use of the integrase strand transfer inhibitor (INSTI) class for the treatment of HIV-infection has pointed to the importance of analyzing the features of HIV-1 subtypes for an improved understanding of viral genetic variability in the occurrence of drug resistance (DR). In this study, we have described the prevalence of INSTI DR in a Russian cohort and the genetic features of HIV-1 integrase sub-subtype A6. We included 408 HIV infected patients who were not exposed to INSTI. Drug resistance mutations (DRMs) were detected among 1.3% of ART-naïve patients and among 2.7% of INSTI-naïve patients. The prevalence of 12 polymorphic mutations was significantly different between sub-subtypes A6 and A1. Analysis of the genetic barriers determined two positions in which subtype A (A1 and A6) showed a higher genetic barrier (G140C and V151I) compared with subtype B, and one position in which subtypes A1 and B displayed a higher genetic barrier (L74M and L74I) than sub-subtype A6. Additionally, we confirmed that the L74I mutation was selected at the early stage of the epidemic and subsequently spread as a founder effect in Russia. Our data have added to the overall understanding of the genetic features of sub-subtype A6 in the context of drug resistance.</style></abstract><accession-num><style face="normal" font="default" size="100%">32752001</style></accession-num><notes><style face="normal" font="default" size="100%">1999-4915Kirichenko, AlinaOrcid: 0000-0002-7116-0138Lapovok, IlyaOrcid: 0000-0002-6328-1415Baryshev, Pavelvan de Vijver, David A M Cvan Kampen, Jeroen J ABoucher, Charles A BParaskevis, DimitriosOrcid: 0000-0001-6167-7152Kireev, DmitryJournal ArticleResearch Support, Non-U.S. Gov'tViruses. 2020 Jul 31;12(8):838. doi: 10.3390/v12080838.</style></notes><custom2><style face="normal" font="default" size="100%">PMC7472261</style></custom2><auth-address><style face="normal" font="default" size="100%">Central Research Institute of Epidemiology, 111123 Moscow, Russia.Viroscience Department, Erasmus Medical Centre, 3015 CE Rotterdam, The Netherlands.Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Goudi, Athens, Greece.</style></auth-address><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record></records></xml>